Natural HIV-1 Nef Polymorphisms Impair SERINC5 Downregulation Activity by Jin, Steven W. et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
Open Access Articles Open Access Publications by UMMS Authors 
2019-11-05 
Natural HIV-1 Nef Polymorphisms Impair SERINC5 
Downregulation Activity 
Steven W. Jin 
Simon Fraser University 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/oapubs 
 Part of the Amino Acids, Peptides, and Proteins Commons, Microbiology Commons, Molecular 
Biology Commons, and the Viruses Commons 
Repository Citation 
Jin SW, Alsahafi N, Kuang XT, Swann SA, Toyoda M, Gottlinger HG, Walker BD, Ueno T, Finzi A, Brumme ZL, 
Brockman MA. (2019). Natural HIV-1 Nef Polymorphisms Impair SERINC5 Downregulation Activity. Open 
Access Articles. https://doi.org/10.1016/j.celrep.2019.10.007. Retrieved from 
https://escholarship.umassmed.edu/oapubs/4053 
Creative Commons License 
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License. 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Articles 
by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
Report
Natural HIV-1 Nef Polymorphisms Impair SERINC5
Downregulation Activity
Graphical Abstract
Highlights
d HIV-1 Nef clones from elite controllers display impaired
SERINC5 antagonism
d Nef polymorphisms associated with variable SERINC5
antagonism are identified
d HLA B*57 and B*08-associated Nef mutations reduce
SERINC5 antagonism
Authors
Steven W. Jin, Nirmin Alsahafi,
Xiaomei T. Kuang, ..., Andrés Finzi,
Zabrina L. Brumme, Mark A. Brockman
Correspondence
mark_brockman@sfu.ca
In Brief
HIV-1 Nef counteracts the cellular
restriction factor SERINC5, but the
importance of this for pathogenesis is
unclear. Jin et al. show that Nef clones
isolated from HIV controllers display
lower ability to antagonize SERINC5, in
part because of viral mutations that are
selected to evade host T cells.
Jin et al., 2019, Cell Reports 29, 1449–1457
November 5, 2019 ª 2019 The Author(s).
https://doi.org/10.1016/j.celrep.2019.10.007
Cell Reports
Report
Natural HIV-1 Nef Polymorphisms Impair
SERINC5 Downregulation Activity
Steven W. Jin,1 Nirmin Alsahafi,2,3 Xiaomei T. Kuang,4 Shayda A. Swann,1 Mako Toyoda,5 Heinrich Göttlinger,6
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SUMMARY
HIV-1 Nef enhances virion infectivity by counteract-
ing host restriction factor SERINC5; however, the
impact of natural Nef polymorphisms on this func-
tion is largely unknown. We characterize SERINC5
downregulation activity of 91 primary HIV-1 sub-
type B nef alleles, including isolates from 45
elite controllers and 46 chronic progressors.
Controller-derived Nef clones display lower ability
to downregulate SERINC5 (median 80% activity)
compared with progressor-derived clones (median
96% activity) (p = 0.0005). We identify 18 Nef
polymorphisms associated with differential func-
tion, including two CTL escape mutations that
contribute to lower SERINC5 downregulation:
K94E, driven by HLA-B*08, and H116N, driven by
the protective allele HLA-B*57. HIV-1 strains en-
coding Nef K94E and/or H116N display lower infec-
tivity and replication capacity in the presence of
SERINC5. Our results demonstrate that natural
polymorphisms in HIV-1 Nef can impair its ability
to internalize SERINC5, indicating that variation in
this recently described function may contribute to
differences in viral pathogenesis.
INTRODUCTION
The HIV-1 Nef protein is crucial for viral pathogenesis (Deacon
et al., 1995; Kestler et al., 1991; Kirchhoff et al., 1995), serving
to modulate diverse cellular events related to vesicular trans-
port, signal transduction and actin cytoskeletal remodeling
that collectively enhance viral infectivity and replication
(Abraham and Fackler, 2012; Cheng-Mayer et al., 1989;
Chowers et al., 1994; Landi et al., 2011; Miller et al., 1994;
Pereira and daSilva, 2016; Terwilliger et al., 1986; Tokarev
and Guatelli, 2011). Nef’s well-characterized abilities to inter-
nalize CD4 and HLA class I from the infected cell surface also
allow HIV-1 to evade antibody-dependent cellular cytotoxicity
(ADCC) and cytotoxic T lymphocytes (CTLs) (Aiken et al.,
1994; Alsahafi et al., 2015, 2017; Collins et al., 1998; Garcia
and Miller, 1991; Schwartz et al., 1996).
Nef-mediated enhancement of viral infectivity was recently
shown to be due in part to its ability to counteract members
of the serine incorporator (SERINC) family of host restriction
factors, of which SERINC5 is most potent (Rosa et al., 2015;
Usami et al., 2015). SERINC5 enters into the membrane of
progeny virions and inhibits fusion with target cells (Sood
et al., 2017). Nef prevents this by internalizing SERINC5
from the cell surface and trafficking it to lysosomes via an en-
dosomal route that is similar to that used to downregulate
CD4 (Shi et al., 2018). Several Nef mutations are reported to
impair its ability to antagonize SERINC5, including G2A,
D123A, and LL165AA, which block myristoylation, dimeriza-
tion, and interaction with AP-2 trafficking complexes, respec-
tively (Foster et al., 2011); however, while HIV-1 nef exhibits
extensive genetic diversity (Brumme et al., 2007; Foster
et al., 2001), these mutations are rare in circulating viral strains
(all >99% conserved; HIV Sequence Database, https://www.
hiv.lanl.gov). Studies to examine the impact of naturally occur-
ring HIV-1 Nef polymorphisms on its ability to counteract
SERINC5 have not been conducted. In a prior study, we
demonstrated that Nef clones isolated from HIV-1 elite con-
trollers, who spontaneously suppress plasma viremia without
therapy (Deeks and Walker, 2007), displayed functional im-
pairments despite the absence of obvious genetic defects
(Mwimanzi et al., 2013). Rather, reduced function was linked
to natural variation in nef sequences, including mutations
selected by the protective HLA allele B*57, indicating that viral
adaptation to host immune selection pressure contributed to
attenuation in at least some cases.
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RESULTS
Primary HIV-1 Nef Alleles Display Variable Abilities to
Internalize SERINC5
To assess whether SERINC5 antagonism differs among circu-
lating HIV-1 strains, we characterized the ability of 91 primary
subtype B nef alleles (representative isolates collected from 45
elite controllers and 46 chronic progressors during untreated
infection) to downregulate SERINC5 using a transfection-based
assay (Figure S1; STAR Methods). The function of each Nef
clone was normalized to that of a control subtype B Nef isolate
(SF2 strain), such that activity better or worse than SF2 Nef is re-
ported as >100% or <100%, respectively. Empty vector and Nef
G2A mutant were included as negative controls. We observed
that controller-derived clones displayed lower SERINC5 down-
regulation activity (median 80%, interquartile range [IQR]
38%–95%) compared with progressor-derived clones (median
96%, IQR 75%–100%) (p = 0.0005, Mann-Whitney test; Fig-
ure 1A; Table S1). To confirm this, we engineered HIV-1 subtype
B reference strain NL4.3 to encode each of 24 nef alleles that
were selected to display a range of SERINC5 downregulation
phenotypes, as well as control nef sequences, and then pro-
duced virions in the absence or presence of SERINC5. We
observed that relative viral infectivity, calculated as the ratio of
infectivity for each strain produced in the presence versus
absence of SERINC5, was variable (Figure 1B). Consistent with
prior studies showing that internalization of SERINC5 is a key
mediator of Nef’s ability to counteract this restriction factor
(Rosa et al., 2015), a strong correlation was found between
SERINC5 downregulation function and viral infectivity
Figure 1. Lower SERINC5 Downregulation by Nef Isolates from HIV Controllers
(A) SERINC5 downregulation function was compared between Nef clones from 45 elite controllers (EC; red) and 46 chronic progressors (CP; blue) (p < 0.001,
Mann-Whitney U-test) using flow cytometry (see Figure S1; STAR Methods). Mean function of each clone (relative to Nef SF2 strain) is reported, on the basis of
triplicate data from three independent experiments. Bars represent median (± interquartile range) of all EC or CP Nef clones.
(B) Relative infectivity of NL4.3 strains encoding 24 nef alleles (14 elite controllers, red; 10 chronic progressors, blue) and 4 controls (G2A, DNef, NL4.3 Nef, and
SF2 Nef, black) was quantified as the quotient of infectivity for each virus generated in the presence of SERINC5 divided by that of the same virus generated in the
absence of SERINC5. All viruseswere tested at least twice in independent experiments.Mean results based on triplicate data from one representative experiment
are shown.
(C) Correlation between SERINC5 downregulation and viral infectivity is shown for data described in (A) and (B) (Spearman R = 0.62, p = 0.0004).
(D) Eight Nef polymorphisms (see Table 1) were confirmed by mutagenesis. Results for mutants that were anticipated to increase (green) or decrease (red)
SERINC5 downregulation function are reported as mean (±SD), on the basis of at least three independent experiments. Significant differences compared with
NL4.3 Nef (100%) are indicated by asterisks (unpaired Student’s t test): *p < 0.05, **p < 0.01, and ***p < 0.001.
(E) Nef expression was assessed by western blot, and percentage relative to NL4.3 Nef is indicated.
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(SpearmanR = 0.62, p = 0.0004; Figure 1C). These data also indi-
cated that 80% normalized SERINC5 downregulation function
was necessary to enhance infectivity in our assays, suggesting
that Nef must maintain relatively high SERINC5 internalization
activity to be effective and, conversely, that relatively modest
impairment of this function may be biologically relevant. While
additional studies are needed to assess the activity of each pri-
mary Nef allele against a wider range of SERINC5 expression
levels, we noted that more than half of controller-derived
clones displayed SERINC5 downregulation activity below 80%,
compared with one-quarter of progressor-derived clones
(p = 0.02, Mann-Whitney test). Together, these results demon-
strate that the ability of Nef to internalize SERINC5 varies among
circulating isolates and that this function is impaired in clones
isolated from elite controllers.
Nef Polymorphisms Are Associated with SERINC5
Downregulation Function
Analysis of our linked genotype-phenotype dataset (see STAR
Methods) identified 18 naturally occurring Nef polymorphisms,
located at 14 codons, that were associated with differential SER-
INC5 downregulation activity (p < 0.05 for all, Mann-Whitney test)
(Table 1). The most statistically significant correlation was
observed at Nef codon 51, where clones encoding threonine
(n = 43) displayed higher activity (median 95.3%) compared
with clones that did not (n = 45, typically asparagine) (81%)
(p = 0.004). We validated eight polymorphisms by introducing
the mutation into a subtype B Nef isolate (NL4.3 strain), each
of which resulted in the expected change in function (p < 0.05
for all, Student’s t test) (Figure 1D). Specifically, downregulation
function was increased modestly for N51T, I114V, and S163C
mutants, each of which displayed5%higher activity compared
with parental Nef; whereas downregulation was impaired for
C55S, K94E, H116N, V148L, and S163R mutants, each of which
displayed 5%–50% lower activity compared with parental Nef.
Of note, Nef codon 51 is associated with viral infectivity (Carl
et al., 2001). Furthermore, Nef codon 163 is located adjacent
to the dileucine motif that is critical for SERINC5 antagonism
(Rosa et al., 2015; Shi et al., 2018) and has been shown previ-
ously to affect Nef binding to clathrin adaptor protein complexes
(Coleman et al., 2006). While steady-state expression of these
Nef mutants was variable (Figure 1E), SERINC5 downregulation
activity did not correlate with our ability to detect Nef by western
blot, indicating that changes in Nef function were unlikely to be
due to differences in protein stability.
SERINC5 Downregulation Correlates with CD4
Internalization
The mechanism of Nef-mediated SERINC5 downregulation
shares several features with that of CD4 downregulation,
including reliance on Nef’s dileucine motif (LL165) (Rosa et al.,
2015; Shi et al., 2018) and trafficking of the internalized receptors
to lysosomes through endosomal compartments (Shi et al.,
2018). To explore potential associations between Nef functions,
we compared the SERINC5 downregulation activity of our 91 Nef
clones with prior results for CD4 and HLA downregulation as well
as protein stability, reported by Mwimanzi et al. (2013) (Figure 2;
Table S1). Notably, SERINC5 downregulation correlated more
strongly with the ability of Nef clones to internalize
CD4 (Spearman R = 0.55, p < 0.0001) compared with HLA
Table 1. Nef Polymorphisms Associated with SERINC5 Downregulation (N R 5, p < 0.05, q < 0.35)
Median Nef Activity Number of Individuals
Codona Amino Acid (AA) With AA Without AA With AA Without AA Impactb p Value q Value
11 A 100.5 86.5 6 75 +14 0.005 0.22
19 K 100.7 85.6 9 82 +15 0.011 0.25
28 D 85.1 93.4 47 44 8 0.047 0.34
43* V 39.4 88.4 5 85 49 0.025 0.33
51 T 95.3 80 43 45 +15 0.004 0.22
51 N 80 96 42 46 16 0.005 0.22
55 C 90.8 73.7 82 9 +17 0.03 0.33
65 E 84.9 98.3 84 7 13 0.01 0.25
94* E 50.3 88.6 5 86 38 0.015 0.28
94 K 88.4 55.2 83 8 +33 0.047 0.34
114 V 89.8 74.9 70 21 +15 0.037 0.34
116 H 95.3 80.6 59 32 +15 0.012 0.25
116* N 80.9 95.3 31 60 14 0.02 0.3
148 V 89.8 66.8 78 13 +23 0.041 0.34
163 C 97.2 83.6 27 64 +14 0.028 0.33
163 R 39.4 87.6 7 84 48 0.033 0.33
170 L 81 91.1 55 36 10 0.049 0.34
182 Q 97.9 85.1 10 81 +13 0.021 0.3
aHXB2-aligned residues; Nef polymorphisms associated with evasion from CD8+ T cells are indicated by asterisks (Brumme et al., 2007).
bMedian Nef activity with AA  median Nef activity without AA, rounded to nearest whole number.
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(R = 0.31, p = 0.0025). In addition, polymorphisms at S163 that
are adjacent to the dileucine motif were similarly associated
with differential ability of Nef to downregulate CD4 (Mwimanzi
et al., 2013). We observed no correlation between Nef expres-
sion levels detected by western blot and downregulation of
SERINC5, CD4, or HLA, indicating that associations between
these functions were not due simply to differences in protein sta-
bility; however, additional studies will be needed to address this.
These results suggest that similar polymorphisms in circulating
nef alleles contribute to variation in SERINC5 and CD4 downre-
gulation functions, while effects on HLA downregulation activity
may be more independent.
Viral Adaptation to T Lymphocytes Contributes to
Variability in SERINC5 Downregulation Activity
Notably, three Nef polymorphisms that were associated with a
substantial reduction in SERINC5 downregulation function,
I43V (49% activity), K94E (38%), and H116N (14%)
(Table 1), are viral ‘‘escape mutations’’ selected in CD8+ T cell
epitopes restricted by HLA-C*03, B*08, and B*57, respectively
(Altfeld et al., 2006; Brumme et al., 2008). This indicates that im-
mune pressure on Nef may attenuate its ability to antagonize
SERINC5. Notably, H116N is often selected early following
infection in individuals expressing the protective B*57 allele
(Brumme et al., 2008), and it is the predominant variant
observed for the HW9 epitope (at position 1 of HTQGYFPDW).
Thus, we speculate that reduced Nef-mediated SERINC5
downregulation may contribute to lower viremia in these cases.
In contrast, K94E is selectedmore slowly in individuals express-
ing the non-protective B*08 allele (Brumme et al., 2008) and 94E
is not the dominant variant observed for the FL8 epitope (at po-
sition 5 of FLKEKGGL) (rather K92R). This suggests that Nef can
adapt to B*08-restricted T cell pressure without enduring the
detrimental impact of this polymorphism on SERINC5 downre-
gulation. Additional studies will be needed to explore these links
between host immune pressure and Nef function in greater
detail.
Figure 2. Associations between Nef Func-
tions and Protein Stability
(A and B) The ability of each elite controller (red) or
chronic progressor (blue) Nef clone to down-
regulate SERINC5was comparedwith that for CD4
(A) and HLA class I (A*02) (B).
(C–E) Next, the ability of each Nef clone to down-
regulate CD4 (C), HLA class I (D), or SERINC5 (E)
was compared with its steady-state protein
expression as detected by western blot.
Correlations were assessed using Spearman rank
test. Data for CD4 and HLA downregulation and
western blot were reported in Mwimanzi et al.,
(2013).
Viral Infectivity and Replication
Capacity Are Impaired by K94E and
H116N
To assess the impact of K94E and
H116N on viral phenotypes, we gener-
ated HIV-1 NL4.3-derived strains encod-
ing these mutations in the absence or presence of SERINC5.
Consistent with downregulation results, we observed lower
SERINC5 surface expression on HEK293T cells producing
wild-type NL4.3 compared with cells producing viruses that
lacked Nef (DNef) or those that encoded Nef mutations that
were anticipated to be detrimental to this function (G2A,
K94E, H116N, or K94E/H116N) (Figure 3A). Moreover, while
viral infectivity was comparable for all NL4.3-derived strains
generated in the absence of SERINC5 (Figure 3B, white bars),
differences in infectivity were seen among viruses generated
in the presence of SERINC5. Specifically, DNef virus was 41-
fold less infectious compared with wild-type NL4.3, while
G2A, K94E, H116N, and double-mutation viruses were 11-,
4-, 3-, and 5.5-fold less infectious than NL4.3, respectively (Fig-
ure 3B, black bars) (p < 0.05 for all, unpaired Student’s t test).
Infectivity of the DNef mutant was modestly impaired in the
absence of SERINC5 (1.7-fold lower compared with NL4.3),
which may be due to SERINC3 expression by HEK293T cells
(Usami et al., 2015). Notably, NL4.3-derived viruses encoding
Nef K94E, H116N, or the double mutation also displayed
reduced infectivity when they passaged using primary periph-
eral blood mononuclear cells (PBMCs) (Figure 3C), indicating
that these polymorphisms altered viral phenotypes in the pres-
ence of endogenous levels of SERINC5. Next, we examined the
impact of these Nef mutations on viral replication using Jurkat-
derived GFP reporter T cells, which express high endogenous
levels of SERINC5 (Rosa et al., 2015). The results of these
studies were consistent with those obtained for SERINC5
downregulation and viral infectivity enhancement by each
mutant. Representative data from one experiment are shown
in Figure 3D. In repeated assays, we observed statistically sig-
nificant delays in viral replication (measured as the slope of viral
cell-to-cell spread over time) for viruses encoding Nef K94E,
H116N, or the double mutation compared with wild-type
NL4.3 (p < 0.05 for all). To confirm that these differences
were due to SERINC5, we generated a SERINC5 knockout
(KO) clone of the Jurkat-GFP reporter T cell line (Figure S2)
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Figure 3. Impact of K94E and H116N Mutants on Nef Function
(A) Representative flow cytometry plots display SERINC5 surface expression on cells co-transfected with pSERINC5-iHA and pNL4.3. MFI of SERINC5 in the
p24+ gate is indicated.
(B and C) Infectivity of NL4.3-derived viruses produced in the absence (white) or presence (black) of SERINC5-iHA (B) or viruses passaged once in healthy donor
PBMCs (C) is shown. Results reflect luminescence (absolute light units [ALUs]) following incubation of TZM-bl reporter cells with a normalized amount of virus.
Data are representative of two independent experiments (B) or PBMCs from three independent donors (C). Unpaired Student’s t test was used to compare each
mutant to NL4.3 (***p < 0.001).
(D and E) Viral replication was examined using Jurkat LTR-GFP R5 cells (D) or those in which SERINC5 was knocked out using CRISPR/Cas9 (Figure S2; STAR
Methods) (E). Viral spread was monitored by flow cytometry. The mean (±SD) fold increase in percentage GFP+ cells (from day 2) is reported for each mutant, on
the basis of triplicate infections. Results are representative of three experiments.
(legend continued on next page)
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and examined the impact of Nef mutations on viral replication
using this line. Representative data from one experiment are
shown in Figure 3E. In repeated assays, we observed no signif-
icant differences in replication capacity between NL4.3-derived
viruses encoding wild-type Nef versus Nef K94E, H116N, or the
double mutation in cells lacking SERINC5 (p > 0.05 for all). Un-
expectedly, NL4.3 viruses encoding Nef mutants displayed a
modest enhancement of replication in our SERINC5 KO cell
line, which was significant for the virus lacking Nef (DNef)
(p < 0.01). We confirmed that this strain lacked Nef (Figure S2)
and also obtained similar results using a second independent
SERINC5 KO clone (data not shown). While the mechanism
for this is unclear, similar results have been observed for
some Nef mutant viruses in other studies (Wu et al., 2019), sug-
gesting that other Nef functions modulate viral replication and
that these may differ in part depending on cell type (Li et al.,
2019; Wu et al., 2019). Finally, to further validate our observa-
tions, we performed viral replication assays in PHA-stimulated
PBMCs infected with equivalent amounts of each virus (5 ng
p24) and measured viral Gag p24 in culture supernatants at
days 0, 3, and 6. Representative data from one experiment
are shown in Figure 3F. Results from repeated assays were
consistent with our prior observations, indicating that viruses
encoding Nef K94E, H116N, or the double mutation displayed
significantly lower replication capacity in primary cells
compared with wild-type NL4.3 (p < 0.01 for all). Together,
these studies demonstrate that K94E and H116N impair viral
infectivity and replication capacity in the presence of SERINC5.
K94E and H116N Selectively Impair Nef-Mediated
SERINC5 Downregulation Function
To determine if the effect of K94E or H116N on SERINC5 down-
regulation was selective, we next tested the ability of Nef mu-
tants encoding these substitutions to internalize CD4 and HLA
class I (Figure 3G, left side). Compared with parental NL4.3
Nef, K94E reduced HLA downregulation activity modestly
(to 87%) (p < 0.05, unpaired Student’s t test) but it had no effect
on CD4 internalization. Conversely, H116N reduced CD4 down-
regulation activity modestly (to 89%) (p < 0.05), but it had no
effect on HLA internalization. All three Nef-mediated downregu-
lation functions were impaired in themutant encoding both K94E
and H116N, indicating that the impact of these polymorphisms
can be additive. In particular, SERINC5 downregulation
activity was reduced markedly in the Nef double mutant (to
19%) (p < 0.001), while more moderate effects were seen for
downregulation of CD4 (69%) and HLA (87%) (p < 0.05 for
both). To explore this further, we identified an elite controller-
derived Nef clone (EC48) encoding E94 and N116 that displayed
poor SERINC5 downregulation activity (32%) but retained mod-
erate CD4 and HLA internalization functions (78% and 92%,
respectively). To confirm that E94 and/or N116 were determi-
nants of impaired SERINC5 downregulation function by this pri-
mary Nef clone, we reverted these polymorphisms to the
consensus residue (Figure 3G, right side). Consistent with results
for NL4.3 Nef, reversion of E94K or N116H alone partially
rescued SERINC5 downregulation activity (to 69% and 59%,
respectively) (p < 0.05 for both); while reversion of both polymor-
phisms enhanced this activity further (to 89%) (p < 0.001). In
contrast to results obtained using NL4.3 Nef, the E94K and dou-
ble reversion mutant displayed lower HLA downregulation activ-
ity compared with the primary Nef clone (56% and 51%, respec-
tively) (p < 0.01), suggesting that unidentified compensatory
polymorphisms in the EC48 nef sequence contributed to main-
tain this function. Together, these results demonstrate that
K94E and H116N reduce Nef’s ability to downregulate SERINC5
to a greater extent compared with CD4 or HLA class I and further
indicate that their impact on all three Nef functions may be
modulated by other sequence variation present in primary nef
alleles.
DISCUSSION
We have demonstrated that circulating HIV-1 subtype B nef al-
leles exhibit substantial variability in SERINC5 downregulation
function. Nef clones isolated from elite controllers displayed
lower in vitro function compared with those from chronic pro-
gressors, suggesting that impaired SERINC5 antagonism may
contribute to lower plasma viremia and slower disease progres-
sion in this rare group of individuals. Consistent with the obser-
vation that even limited amounts of SERINC5 incorporation
into viral particles reduces infectivity (Trautz et al., 2016), we
found that Nef-mediated infectivity enhancement required
80% normalized SERINC5 downregulation activity in our as-
says, a threshold that was not met by 51% of elite controller-
derived Nef clones.
While a prior study examined the ability of diverse HIV and
SIV Nef isolates to antagonize SERINC5 (Heigele et al., 2016),
it assessed relatively few (15) HIV-1 group M clones. Our
analysis of 91 HIV-1 subtype B Nef clones offers greater po-
wer to explore functional variation among patient-derived se-
quences. Here, we identified 18 polymorphisms that were
associated with differential SERINC5 downregulation activity.
We validated 8 of these polymorphisms, including 2 well-char-
acterized CD8+ T cell escape mutations, K94E and H116N,
using site-directed mutagenesis. While mechanisms respon-
sible for impaired SERINC5 internalization by primary nef
alleles or mutants have not been defined in this study, it is
intriguing that K94E and H116N had only modest effects on
Nef’s ability to downregulate CD4 or HLA class I, suggesting
that K94 and H116 lie within domains of Nef that are particu-
larly important to antagonize SERINC5 rather than to inter-
nalize CD4 or HLA.
Our results indicate that Nef polymorphisms can impair
viral infectivity and replication in the presence of SERINC5;
(F) Replication was also assessed following infection of PHA-stimulated PBMCs. Supernatant was harvested on days 0, 3, and 6 and viral p24 quantified using
ELISA. Results are representative of PBMCs from three donors.
(G) The ability of NL4.3 Nef mutants encoding K94E and/or H116N or EC48 Nef reversionmutants encoding E94K and/or N116H to downregulate SERINC5, CD4,
and HLA is shown. Bars represent the mean (±SD) function, normalized to control, in at least three experiments. Unpaired Student’s t test was used to compare
each mutant with control (*p < 0.05, **p < 0.01, and ***p < 0.001).
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however, additional work is needed to assess the importance of
Nef-mediated SERINC5 antagonism for HIV-1 pathogenesis.
Our ability to address this question is hindered by an incomplete
understanding of SERINC5 restriction mechanisms and by Nef’s
continuously evolving role as a mediator of viral infectivity
(Li et al., 2019; Wu et al., 2019). A limitation of this study is that
we did not directly measure SERINC5 incorporation into the
virions of strains encoding Nef mutants. Strong correlations be-
tween SERINC5 downregulation activity and viral infectivity sug-
gest that internalization of SERINC5 is themost important contri-
bution of Nef in this setting, but we cannot rule out a role for other
known (or unknown) Nef functions. In addition, HIV-1 Envelope
modulates viral sensitivity to SERINC5 (Beitari et al., 2017), but
its relative impact compared with Nef has not been elucidated,
and potential functional interactions between primary nef and
env alleles have not been studied. Furthermore, Nef’s ability to
counteract SERINC5 is dependent on the expression levels of
both proteins (Schulte et al., 2018; Trautz et al., 2016), which
may not be recapitulated fully by our in vitro assays. While our re-
sults using primary cells are consistent with data collected using
T cell lines, validation using other cell types is needed. Despite
these limitations, our study provides strong evidence that natural
variation in Nef-mediated SERINC5 antagonism function con-
tributes to clinical outcomes following HIV-1 infection. Our data
highlight the constraints placed on Nef by the interplay between
adaptive host immunity and intrinsic host restriction mecha-
nisms, which may result in viral attenuation during the course
of natural infection.
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KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Beta-Actin, Mouse clone AC-15 Sigma-Aldrich Cat # A1978; RRID: AB_476692
CD4, Mouse Clone RPA-T4 (APC) BD Biosciences Cat # 555349; RRID: AB_398593
HA.11 Epitope Tag antibody (Alexa Fluor 647) BioLegend Cat # 682404; RRID:AB_2566616
HIV-1 Core Antigen, Mouse clone KC57 (RD1) Beckman Coulter Cat # 6604667
Human HLA-A2 Antibody, Mouse clone BB7.2 (R-PE) BD Biosciences Cat # 558570; RRID: AB_647220
Mouse IgG, Goat polyclonal, minimal x-reactivity (HRP) BioLegend Cat # 405306; RRID: AB_315009
Nef, Rabbit polyclonal NIH AIDS Reagents Program, gift
of R Swanstrom (Shugars et al., 1993)
Cat # 2949
Rabbit IgG, Donkey polyclonal, minimal x-reactivity
(HRP)
BioLegend Cat # 406401; RRID: AB_2099368
SERINC5, Rabbit polyclonal Abcam Cat # ab204400
Bacterial and Virus Strains
E. cloni 10G SOLOs Chemically Competent Cells Lucigen Cat # 0106-2
One Shot Stbl3 Chemically Competent E. coli Invitrogen Cat # C737303
Biological Samples
Human Peripheral Blood Mononuclear Cells, Frozen Stem Cell Technologies Cat # 70025
HIV-1 subtype B Nef clones Mwimanzi et al., 2013 N/A
Chemicals, Peptides, and Recombinant Proteins
Lectin from Phaseolus vulgaris Erythrohemagglutinin
(PHA-E)
Sigma-Aldrich Cat # L8629
Human Recombinant IL-2 StemCell Technologies, Inc. Cat # 78036
Fixation/Permeabilization Solution Kit BD Biosciences Cat # 554714
DNAfectin 2100 Transfection Reagent Applied Biological Materials Cat # G2100
TrypLE Express Enzyme (1X), phenol red GIBCO Cat # 12605010
Critical Commercial Assays
Gene Pulser MXcell Electroporation System Bio-Rad Cat # 165-2670
96-Well Electroporation Plates Bio-Rad Cat # 1652681
HIV-1 p24 ELISA Kit XpressBio Cat # XB-1000
Steady-Glo Luciferase Assay System Promega Cat # E2550
Deposited Data
HIV-1 subtype B Nef sequences Mwimanzi et al., 2013 GenBank accession JX171199-
JX171243 (controllers) and
JX440926-JX440971 (progressors)
Experimental Models: Cell Lines
CEM-A*02, human T cell Anmole et al., 2015 N/A
HEK293T, human kidney cell American Type Culture Collection Cat # CRL-3216 RRID: CVCL_0063
Jurkat LTR-GFP CCR5+ (JLTRG-R5), human T cell NIH AIDS Reagents Program, gift
of O Kutsch (Kutsch et al., 2004)
Cat #11586
Jurkat LTR-GFP CCR5+ (JLTRG-R5) SERINC5
knockout, human T cell
This paper N/A
TZM-bl, human carcinoma cell, derived from HeLa NIH AIDS Reagents Program, gift
of JC Kappes and X Wu (Derdeyn
et al., 2000; Platt et al., 1998;
Wei et al., 2002)
Cat # 8129-442; RRID: CVCL_B478
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LEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Mark
Brockman (mark_brockman@sfu.ca).
All unique/stable reagents generated in this study are available from the Lead Contact with a completed Materials Transfer
Agreement.
EXPERIMENTAL MODELS AND SUBJECT DETAILS
Human subjects
All HIV-infected participants were recruited from the Boston (USA) area and provided written informed consent. None were receiving
antiretroviral therapy at the time of specimen collection. Elite controllers (EC) were defined as having an untreated HIV-1 plasma viral
load (pVL) of less than 50 RNA copies/mL for at least 2 years. Chronic progressors (CP) were defined as having an untreated pVL of at
least 10,000 RNA copies/mL. The EC cohort (N = 45) displayed a median pVL of 2 RNA copies/mL (interquartile range [IQR] 0.2 – 14)
and amedian CD4 count of 811 cells per mm3 (IQR 612 – 1022). The CP cohort (N = 46) displayed amedian pVL of 80,500 RNA copies
per mL (IQR 25,121 – 221,250) and a median CD4 count of 293 cells per mm3 (IQR 73 – 440). Information regarding the sex of EC
participants (84% male) is indicated in Table S1. Information regarding the sex of CP participants and the age of all participants
was not recorded at the time of specimen collection, and therefore this data is unavailable. This study was approved by the Research
Ethics Boards at the Massachusetts General Hospital (Boston, MA USA) and Simon Fraser University (Burnaby, BC Canada).
Primary Cells
Human peripheral blood mononuclear cells (PBMC) from healthy HIV-uninfected donors were purchased from StemCell Technolo-
gies and maintained in RPMI-1640 media supplemented with 10% FBS, 2mM L-glutamine, 1000 U/mL Penicillin, and 1 mg/mL
Streptomycin (all from Sigma-Aldrich), plus 50 U/mL human recombinant IL-2 (NIH AIDS Reagents Program) at 37C with 5%
CO2. All donors were male.
Cell lines
CEM-A*02 cells were derived from CEM (a female human acute lymphoblastic leukemia T cell line) by stably transduction of
HLA-A*02:01 using a retroviral vector (murine stem cell virus; Clontech), and maintained in RPMI-1640 media supplemented with
10% FBS, 2 mM L-glutamine, 1000 U/mL Penicillin and 1 mg/mL Streptomycin (all from Sigma-Aldrich) at 37C with 5% CO2. Jurkat
LTR-GFP CCR5+ reporter cells (JLTRG-R5), which are derived from Jurkat (a male human acute T cell leukemia cell line), were main-
tained using the same conditions. HEK293T cells (a human embryonic kidney cell line) and TZM-bl reporter cells (a female human
carcinoma cell line, derived from HeLa) were cultured in DMEM supplemented with 10% FBS, 2 mM L-glutamine, 1000 U/mL
Penicillin and 1 mg/mL Streptomycin.
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Oligonucleotides
Nef_Forward Primer (AGAGCACCGG CGCGCCTCCA
CATACCTASA AGAATMAGAC ARG)
This paper N/A
Nef_Reverse Primer (GCCTCCGCGG ATCGATCAGG
CCACRCCTCC CTGGAAASKC CC)
This paper N/A
Recombinant DNA
pHEF-VSVG NIH AIDS Reagent Program, gift of L-J
Chang (Chang et al., 1999)
Cat # 4693
pMaxFP-Green-N Amaxa Cat # VDF-1012
pNL4-3, infectious HIV-1 molecular clone NIH AIDS Reagents Program, gift of
M Martin (Adachi et al., 1986)
Cat # 114
pSELECT-GFPzeo-mcs InvivoGen Cat # psetgz-mcs
pSELECT-DGFP-zeo-mcs This paper N/A
pX330-U6-Chimeric_BB-CBh-hSpCas9 Addgene, provided by F Zhang (Cong
et al., 2013; Ran et al., 2013)
Cat # 42230; RRID: Addgene_42230
Software and Algorithms
FlowJo 9.9.5 FlowJo, LLC FlowJo
Prism 7 Graphpad Prism
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METHOD DETAILS
Reagents
The following materials were obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 NL4-3 infectious
molecular clone (pNL4-3), from Dr. Malcolm Martin (Adachi et al., 1986); Jurkat LTR-GFP CCR5+ cells (JLTRG-R5), from Dr. Olaf
Kutsch (Kutsch et al., 2004; Ochsenbauer-Jambor et al., 2006); and TZM-bl cells from Dr. John C. Kappes, and Dr. XiaoyunWu (Der-
deyn et al., 2000; Platt et al., 2009; Platt et al., 1998; Takeuchi et al., 2008; Wei et al., 2002).
Generation of HIV-1 nef expression and proviral constructs
HIV-1 subtype-B nef alleles were amplified from plasma viral RNA. A single phylogenetically representative nef clone was isolated
from each participant in a previous study (Mwimanzi et al., 2013). Nef alleles were transferred into pSELECT-GFPzeo (InvivoGen),
which features a composite hEF1-HTLV promoter driving nef and an independent CMV promoter driving expression of GFP. To
do this, we modified the multiple cloning site in pSELECT-GFPzeo to incorporate unique Asc I and Sac II sites. Each nef gene
was amplified by PCR using degenerate primers incorporating these restriction sites (Fwd: 50-AGAGCACCGG CGCGCCTCCA CAT
ACCTASA AGAATMAGAC ARG-30, HXB2 nt 8746-8772 underlined, Asc I site in bold; Rev: 50-GCCTCCGCGG ATCGATCAGG
CCACRCCTCC CTGGAAASKC CC-30, HXB2 nt 9474-9449 underlined, SacII site bolded). The same strategy was used to clone
nef from HIV-1 subtype B reference strains SF2 and NL4.3, which served as positive controls. Point mutations were introduced
into nef sequences using overlap extension PCR, including G2A substitutions in both reference clones that served as negative con-
trols. All nef clones and mutations were validated by Sanger sequencing.
Nef sequences and mutants were introduced into the HIV-1 subtype B NL4.3 reference strain backbone as described previously
(Mwimanzi et al., 2013). Wild-type NL4.3 served as a positive control, while strains encoding G2A or premature stop codons at po-
sitions 31 and 33 (referred to as DNef) were used as negative controls for infectivity and replication assays.
Nef polymorphisms are reported using HXB2 numbering convention (Korber et al., 1998). Sequences were pairwise-aligned to the
reference strain HXB2 (GenBank accession number K03055) and insertions with respect to HXB2 were removed using an in-house
alignment algorithm based on the HyPhy platform (Pond et al., 2005).
Generation of SERINC5 knockout Jurkat LTR-GFP reporter cells
Jurkat T cell lines express high endogenous SERINC5 (Rosa et al., 2015). CRISPR/Cas9 methods were used to disrupt the SERINC5
gene in Jurkat LTR-GFP R5 cells. To do this, cells were co-transfected with px330-based plasmids (Cong et al., 2013; Ran et al.,
2013) encoding target sequences described by Rosa et al. (2015) along with pMAX-GFP for use as a transfection control. Following
transfection, GFP+ cells were isolated as single cells into R20+ media (RPMI-1640 supplemented with 2 mM L-glutamine, 1000 U/ml
Penicillin, 1 mg/ml Streptomycin and 20% vol/vol FBS, all from Sigma-Aldrich) and expanded in 96-well flat bottom plates. Stable
SERINC5 knockout (KO) clones were validated by western blot using a rabbit polyclonal anti-SERINC5 antiserum (Abcam).
SERINC5 downregulation assays
To assess Nef-mediated internalization of SERINC5 from the cell surface, 13 106 CEM-A*02 T cells were co-transfected with 1 mg of
pSELECT-GFPzeo encoding nef and 5 mg of pSELECT-SERINC5-internal HA tag (iHA)-DGFP (sub-cloned from pBJ5-SERINC5(iHA)
(Usami et al., 2015) by electroporation in 150 mL OPTI-memmedium (Thermo Fisher Scientific) using a BioRad GenePulser MXCellTM
instrument (square wave protocol: 250 V, 2000 mF, infinite U, 25 ms single pulse). Cultures were recovered for 20 hours with 350 ml of
R10+ medium (RPMI-1640 supplemented with 2 mM L-glutamine, 1000 U/ml Penicillin, 1 mg/ml Streptomycin and 10% vol/vol FBS,
all from Sigma-Aldrich) at 37C plus 5% CO2. Following this, 2.53 10
5 cells were stained with 0.5 mg of Alexa Fluor 647 anti-HA.11
(BioLegend) and analyzed by flow cytometry for GFP expression (as amarker for transfected cells) and cell surface HA staining (as an
indicator of SERINC5 expression) using a Millipore Guava 8HT instrument. A minimum of 25,000 cells were assessed in each
case. The median fluorescence intensity (MFI) values of SERINC5 for each Nef clone were normalized to the positive
(pSELECT-nefWT-GFPzeo) and negative (pSELECT-Dnef) controls using the formula: (MFIDNef – MFICLONE)/(MFIDNef – MFIWT) 3
100, such that Nef function less than or greater than wild-type Nef is represented by values of < 100% or > 100%, respectively.
The activity of each primary Nef clone was normalized to Nef (SF2 strain) to be consistent with our previous studies. Since point mu-
tations were introduced into Nef (NL4.3 strain), that strain was used to normalize results from those studies. The SERINC5 downre-
gulation activity of each Nef clone is reported as the mean ± SD based on at least three independent transfection experiments.
CD4 and HLA class I downregulation assays
Selected primary Nef clones and mutants were evaluated for their ability to internalize CD4 and HLA-A*02 (as a representative class I
HLA molecule) as described previously (Mwimanzi et al., 2013). Briefly, 2.53 105 transfected CEM-A*02 CD4 T cells from the same
pool of transfected cells described above were stained with anti-CD4-APC and anti-HLA-A*02-PE (BD Biosciences). The MFI of sur-
face CD4 and HLA-A*02 expression levels in the GFP+ cell subsets were determined by flow cytometry and normalized using the
same formula as described for SERINC5. The CD4 or HLA downregulation activity of each Nef clone or mutant is reported as the
mean ± SD based on at least three independent transfection experiments.
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Viral infectivity assays
Virus stocks were generated by co-transfecting 83 105 HEK293T cells seeded in one well of a 6-well plate with 2.5 mg of pNL4.3 and
either 30 ng of pSELECT-SERINC5(iHA)-DGFP or empty pSELECT-DGFP vector using DNAfectin 2100 (Applied Biological Materials).
Culture supernatants were harvested 48 hours post-transfection, aliquoted and stored at 80C prior to use. To assess SERINC5
surface expression on virus-producing cells, the transfected cells were collected using Trypsin/EDTA (Sigma-Aldrich) and dissoci-
ated cells were prepared for analysis by flow cytometry. Briefly, cells were stained with 0.5 mg of Alexa Fluor 647 anti-HA.11
(BioLegend), washed to remove unbound antibody, treated with Fix/Perm solution (BD Biosciences), and then stained with PE
anti-Gag/p24 (KC57; Beckman Coulter). A minimum of 10,000 cells was assessed in each case. Virus particles in the supernatant
were quantified by p24 ELISA (XpressBio) and viral infectivity was determined by exposing 1 3 104 TZM-bl reporter cells to a
standardized amount of each virus (1 or 5 ng p24) on a 96-well flat bottom plate. Luminescence activity (absolute light units, ALU)
of TZM-bl cells was measured 48 hours later using the Steady-Glo Luciferase Assay (Promega) and a Tecan Infinite M200 PRO
plate reader. The relative infectivity of each viral strain (i.e., the difference between viruses generated in the presence versus absence
of SERINC5) was calculated using the following formula: (ALU of virus produced by SERINC5-expressing HEK293T cells) / (ALU of
virus produced by SERINC5-negative HEK293T). The infectivity of each viral strain produced by HEK293T cells was assessed in at
least three independent experiments.
To determine the infectivity of viruses produced by primary cells, VSV-g pseudotyped viruses were generated using HEK293T cells
in the absence of SERINC5, as described above and in Kinloch et al. (2018), and then used to infect PBMC isolated from HIV-unin-
fected donors. Briefly, 5 3 105 activated PBMC (generated by pre-stimulation with 5 mg/ml PHA for 72 hours) were incubated with
5 ng p24 of each virus in 96-well U bottom plates by spinoculation (800 x g for 1 hour at room temperature). PBMCwere subsequently
incubated for 8 hours at 37C and unbound virus was removed by washing with PBS. Cells were then resuspended in R10+ media
supplemented with 100 U/mL human IL-2 (NIH AIDS Reagent Program). Culture supernatants were collected at 48 and 72 hours
post-infection and newly produced viruses were quantified using p24 ELISA. Viral infectivity was measured by exposing TZM-bl re-
porter cells to a standardized amount of each virus, as described above. The infectivity of each viral strain produced by PBMC was
assessed in at least two independent experiments.
Viral replication capacity assays
Replication capacity was determined using viruses produced in the absence of SERINC5 by infecting 1 3 106 Jurkat LTR-GFP
CCR5+ and Jurkat SERINC5 KO LTR-GFP CCR5+ cells at a multiplicity of infection (MOI) of 0.003. The proportion of GFP+ cells
in culture wasmeasured on days 2 to 8 and results are shown as the fold-increase in%GFP+ cells based on day 2 values. Replication
capacity of each viral strain was assessed in at least three (Jurkat LTR-GFP R5) or two (SERINC5 KO cells) independent experiments.
To examine potential differences in replication more robustly, we calculated the natural log slope of viral spread during the exponen-
tial phase of growth for each virus, as described in Brockman et al. (2006). The resulting slope values from independent experiments
were then compared to wild-type NL4.3 using the unpaired Student’s t test to identify statistically significant differences.
To examine replication capacity in primary cells, VSV-g pseudotyped viruses produced using HEK293T cells in the absence of
SERINC5, as described above and in Kinloch et al. (2018), were used to infect PBMC isolated from HIV-uninfected donors. Briefly,
53 105 activated PBMC (generated by pre-stimulation with 5 mg/ml PHA for 72 hours) were incubated with 5 ng p24 of each virus in
96-well U bottom plates by spinoculation (800 x g for 1 hour at room temperature). PBMC were subsequently cultured for 8 hours at
37C in R10+ media and unbound virus was removed by washing cells with PBS. Cells were then resuspended in R10+ media sup-
plemented with 100 U/mL human IL-2 (NIH AIDS Reagent Program). Culture supernatants were collected on days 0, 3, 6, and 9, and
newly produced viruses were quantified using p24 ELISA. The replication capacity of each viral strain in PBMCwas assessed in three
independent donors. To examine potential differences in replication more robustly, we calculated the natural log slope of viral spread
during the exponential phase of growth for each virus, as described in Brockman et al. (2006). The resulting slope values from inde-
pendent experiments were then compared to wild-type NL4.3 using the unpaired Student’s t test to identify statistically significant
differences.
Western blot
To assess steady-state protein expression of primary Nef alleles and mutants, 53 106 CEM-A*02 CD4 T cells were transfected with
10 mg of pSELECT-nef-GFPzeo alone via the electroporation settings as described above. After 24 hours, cells were pelleted, lysed
and prepared as described previously (Mwimanzi et al., 2013). Nef was labeled using a polyclonal rabbit serum (NIH AIDS Reagent
Program) (1:2,000) followed by staining with donkey anti-rabbit HRP-conjugated secondary antibody (GE Healthcare) (1:30,000). To
validate CRISPR/Cas9-mediated knockout of SERINC5 in the Jurkat LTR-GFP cells, 23 106 parental or KO cells were pelleted and
lysed. SERINC5 protein expression was detected using rabbit polyclonal anti-SERINC5 antibody (Abcam ab204400) at a 1:300
dilution, followed by staining with donkey anti-rabbit HRP-conjugated secondary antibody (GE Healthcare) (1:30,000). Proteins
were detected using Clarity Western ECL substrate (Bio-Rad) and visualized on an ImageQuant LAS 4000 imager (GE healthcare).
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QUANTIFICATION AND STATISTICAL ANALYSIS
Nef polymorphisms associated with differential in vitro SERINC5 downregulation function were identified using a custom Perl script.
For every Nef polymorphism present at > 5% in our dataset (i.e., 5 or more unique HXB-aligned sequences), clones were repeatedly
grouped according to the presence versus absence of the observed variant and the nonparametric Mann-Whitney U-test was then
used to compare median SERINC5 downregulation function between groups. Multiple comparisons were addressed using q-values,
the p value analog of the false discovery rate (FDR). The FDR is the expected proportion of false positives among results deemed
significant at a given p value threshold (e.g., at a q % 0.2, we expect 20% of identified associations to be false positives).
All other statistical analyses were performed using Prism v.7 (Graphpad). Results of two-tailed tests were considered significant if
the p value was less than 0.05. The nonparametric Mann-Whitney U test was used to compare differences in median Nef function
between EC and CP cohorts. The parametric Students t test was used to compare differences in the mean Nef function of viral mu-
tants. For parametric tests, normality of the data was assessed using the Kolmogorov-Smirnov test. Multiple comparisons were ad-
dressed using q-values, the p value analog of the false discovery rate (FDR). The FDR is the expected proportion of false positives
among results deemed significant at a given p value threshold (e.g., at a q% 0.2, we expect 20%of identified associations to be false
positives). Following normalization of data positive and negative controls, we used the unpaired t test to determine if the observed
function of each Nef mutant was significantly different from that of the wild-type Nef.
DATA AND CODE AVAILABILITY
The Nef downregulation data that support this study are provided in Table S1. Nef sequences are available at GenBank (accession
numbers JX171199-JX171243 for elite controllers; JX440926-JX440971 for chronic progressors). The code for scripts that were used
to align nef sequences and to analyze the linked Nef sequence-function dataset is available by contacting the Lead Author.
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